ECSP034600A - Compuestos de lactama - Google Patents

Compuestos de lactama

Info

Publication number
ECSP034600A
ECSP034600A EC2003004600A ECSP034600A ECSP034600A EC SP034600 A ECSP034600 A EC SP034600A EC 2003004600 A EC2003004600 A EC 2003004600A EC SP034600 A ECSP034600 A EC SP034600A EC SP034600 A ECSP034600 A EC SP034600A
Authority
EC
Ecuador
Prior art keywords
lactama
compounds
alaninyl
methylbutyryl
benzazepin
Prior art date
Application number
EC2003004600A
Other languages
English (en)
Spanish (es)
Inventor
Varghese John
Eugene D Thorsett
Jeffrey Nissen
Lee H Latimer
James E Audia
Jay S Tung
Stacey Leigh Mcdaniel
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of ECSP034600A publication Critical patent/ECSP034600A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/16—Benzazepines; Hydrogenated benzazepines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicinal Preparation (AREA)
EC2003004600A 2000-11-17 2003-05-13 Compuestos de lactama ECSP034600A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US24955200P 2000-11-17 2000-11-17

Publications (1)

Publication Number Publication Date
ECSP034600A true ECSP034600A (es) 2003-06-25

Family

ID=22943982

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2003004600A ECSP034600A (es) 2000-11-17 2003-05-13 Compuestos de lactama

Country Status (33)

Country Link
US (1) US20050261495A1 (https=)
EP (1) EP1341531B1 (https=)
JP (1) JP4116437B2 (https=)
KR (1) KR100819679B1 (https=)
CN (1) CN1486184A (https=)
AR (1) AR035927A1 (https=)
AU (2) AU4319202A (https=)
BR (1) BR0115427A (https=)
CA (1) CA2427227C (https=)
CY (1) CY1106366T1 (https=)
CZ (1) CZ20031351A3 (https=)
DE (1) DE60126132T2 (https=)
DK (1) DK1341531T3 (https=)
DZ (1) DZ3453A1 (https=)
EA (1) EA005954B1 (https=)
EC (1) ECSP034600A (https=)
ES (1) ES2278804T3 (https=)
HR (1) HRP20030383B1 (https=)
HU (1) HU228117B1 (https=)
IL (2) IL155960A0 (https=)
MX (1) MXPA03004292A (https=)
MY (1) MY134559A (https=)
NO (1) NO324324B1 (https=)
NZ (1) NZ525854A (https=)
PE (1) PE20020802A1 (https=)
PL (1) PL212199B1 (https=)
PT (1) PT1341531E (https=)
SI (1) SI1341531T1 (https=)
SK (1) SK288065B6 (https=)
TW (1) TWI305204B (https=)
UA (1) UA74849C2 (https=)
WO (1) WO2002047671A2 (https=)
ZA (1) ZA200303789B (https=)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7468365B2 (en) 2000-11-17 2008-12-23 Eli Lilly And Company Lactam compound
UA74849C2 (en) * 2000-11-17 2006-02-15 Lilly Co Eli Lactam
US8114886B2 (en) 2005-04-08 2012-02-14 Daiichi Sankyo Company, Limited Pyridylmethylsulfone derivative
WO2006123182A2 (en) 2005-05-17 2006-11-23 Merck Sharp & Dohme Limited Cyclohexyl sulphones for treatment of cancer
US8258302B2 (en) 2006-01-31 2012-09-04 Api Corporation Method for producing benzazepinone
CA2676715A1 (en) 2007-02-12 2008-08-21 Merck & Co., Inc. Piperazine derivatives for treatment of ad and related conditions
EP2193117A1 (en) * 2007-07-16 2010-06-09 Wyeth a Corporation of the State of Delaware Inhibitors of beta amyloid production
MX2010001754A (es) 2007-08-14 2010-05-14 Lilly Co Eli Derivados de azepina como inhibidores de gamma secretasa.
TW200920362A (en) 2007-09-11 2009-05-16 Daiichi Sankyo Co Ltd Alkylsulfone derivatives
KR101595238B1 (ko) 2007-12-21 2016-02-18 리간드 파마슈티칼스 인코포레이티드 선택적 안드로겐 수용체 조절제(ｓａｒｍ) 및 이의 용도
WO2009128057A2 (en) 2008-04-18 2009-10-22 UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN et al Psycho-pharmaceuticals
WO2010114780A1 (en) 2009-04-01 2010-10-07 Merck Sharp & Dohme Corp. Inhibitors of akt activity
US8859776B2 (en) 2009-10-14 2014-10-14 Merck Sharp & Dohme Corp. Substituted piperidines that increase p53 activity and the uses thereof
US8999957B2 (en) 2010-06-24 2015-04-07 Merck Sharp & Dohme Corp. Heterocyclic compounds as ERK inhibitors
CA2805265A1 (en) 2010-08-02 2012-02-09 Merck Sharp & Dohme Corp. Rna interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (ctnnb1) gene expression using short interfering nucleic acid (sina)
WO2012024170A2 (en) 2010-08-17 2012-02-23 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF HEPATITIS B VIRUS (HBV) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
WO2012030685A2 (en) 2010-09-01 2012-03-08 Schering Corporation Indazole derivatives useful as erk inhibitors
US9242981B2 (en) 2010-09-16 2016-01-26 Merck Sharp & Dohme Corp. Fused pyrazole derivatives as novel ERK inhibitors
WO2012040444A2 (en) * 2010-09-24 2012-03-29 Bristol-Myers Squibb Company Treatment of patients with incipient alzheimer's disease
WO2012058210A1 (en) 2010-10-29 2012-05-03 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACIDS (siNA)
EP2654748B1 (en) 2010-12-21 2016-07-27 Merck Sharp & Dohme Corp. Indazole derivatives useful as erk inhibitors
EP2770987B1 (en) 2011-10-27 2018-04-04 Merck Sharp & Dohme Corp. Novel compounds that are erk inhibitors
CN102690231B (zh) * 2012-04-11 2014-07-09 南京友杰医药科技有限公司 治疗阿尔茨海默病潜在药物司马西特的合成方法
WO2013165816A2 (en) 2012-05-02 2013-11-07 Merck Sharp & Dohme Corp. SHORT INTERFERING NUCLEIC ACID (siNA) COMPOSITIONS
CA2884309A1 (en) 2012-09-07 2014-03-13 Massachusetts Eye And Ear Infirmary Methods and compositions for regenerating hair cells and/or supporting cells from differentiated cochlear cells or differentiated utricular cells by modulation of notch and cmyc activity
CA2883896C (en) 2012-09-07 2023-03-07 Massachusetts Eye & Ear Infirmary Treating hearing loss
WO2014052563A2 (en) 2012-09-28 2014-04-03 Merck Sharp & Dohme Corp. Novel compounds that are erk inhibitors
ME02925B (me) 2012-11-28 2018-04-20 Merck Sharp & Dohme Kompozicije i postupci za liječenje kancera
TW201429969A (zh) 2012-12-20 2014-08-01 Merck Sharp & Dohme 作爲ｈｄｍ２抑制劑之經取代咪唑吡啶
WO2014120748A1 (en) 2013-01-30 2014-08-07 Merck Sharp & Dohme Corp. 2,6,7,8 substituted purines as hdm2 inhibitors
JP6319912B2 (ja) 2013-04-19 2018-05-09 国立大学法人 岡山大学 アミロイドβ蛋白質により誘発される認知障害の治療剤およびアルツハイマー病治療薬、ならびにこれらに関連する治療方法および病態解析方法
US20160194368A1 (en) 2013-09-03 2016-07-07 Moderna Therapeutics, Inc. Circular polynucleotides
EP3094323A4 (en) 2014-01-17 2017-10-11 Ligand Pharmaceuticals Incorporated Methods and compositions for modulating hormone levels
EP3212773B1 (en) 2014-10-29 2021-09-15 Massachusetts Eye and Ear Infirmary Efficient delivery of therapeutic molecules to cells of the inner ear
JP6840774B2 (ja) 2016-05-16 2021-03-10 ザ ジェネラル ホスピタル コーポレイション 肺上皮エンジニアリングにおけるヒト気道幹細胞
US10975084B2 (en) 2016-10-12 2021-04-13 Merck Sharp & Dohme Corp. KDM5 inhibitors
EP3706747B1 (en) 2017-11-08 2025-09-03 Merck Sharp & Dohme LLC Prmt5 inhibitors
US10947234B2 (en) 2017-11-08 2021-03-16 Merck Sharp & Dohme Corp. PRMT5 inhibitors
WO2019148067A1 (en) 2018-01-26 2019-08-01 Massachusetts Eye And Ear Infirmary Treatment of hearing loss
WO2020033282A1 (en) 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Prmt5 inhibitors
WO2020033288A1 (en) 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Prmt5 inhibitors
EP3833669A4 (en) 2018-08-07 2022-05-11 Merck Sharp & Dohme Corp. PRMT5 INHIBITORS
US11981701B2 (en) 2018-08-07 2024-05-14 Merck Sharp & Dohme Llc PRMT5 inhibitors
AU2020257397B2 (en) 2019-04-19 2026-02-26 Ligand Pharmaceuticals Inc. Crystalline forms and methods of producing crystalline forms of a compound
US12595248B2 (en) 2019-12-17 2026-04-07 Merck Sharp & Dohme Llc PRMT5 inhibitors
CN115003303B (zh) 2019-12-17 2024-03-08 默沙东公司 Prmt5抑制剂
EP4076460B1 (en) 2019-12-17 2026-01-21 Merck Sharp & Dohme LLC 1,4-dihydro-2h-spiro[isoquinoline-3,4'-piperidine derivatives as prmt5 inhibitors for the treatment of cancer
JP7589247B2 (ja) 2019-12-17 2024-11-25 メルク・シャープ・アンド・ドーム・エルエルシー Ｐｒｍｔ５阻害剤
JP2025511436A (ja) 2022-09-02 2025-04-16 メルク・シャープ・アンド・ドーム・エルエルシー エキサテカン由来トポイソメラーゼ－１阻害薬医薬組成物及びその使用
CN120417935A (zh) 2022-10-25 2025-08-01 默沙东有限责任公司 依喜替康衍生的adc接头-载荷及其药物组合物和用途
US20240207425A1 (en) 2022-12-14 2024-06-27 Merck Sharp & Dohme Llc Auristatin linker-payloads, pharmaceutical compositions, and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA002100B1 (ru) * 1996-12-23 2001-12-24 Элан Фармасьютикалз, Инк. ЦИКЛОАЛКИЛЬНЫЕ СОЕДИНЕНИЯ, ЛАКТАМЫ, ЛАКТОНЫ И РОДСТВЕННЫЕ СОЕДИНЕНИЯ, СОДЕРЖАЩИЕ ИХ ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ И СПОСОБЫ ИНГИБИРОВАНИЯ ВЫСВОБОЖДЕНИЯ И/ИЛИ СИНТЕЗА β-АМИЛОИДНОГО ПЕПТИДА С ПОМОЩЬЮ УКАЗАННЫХ СОЕДИНЕНИЙ
WO1999067219A1 (en) * 1998-06-22 1999-12-29 Elan Pharmaceuticals, Inc. Compounds for inhibiting beta-amyloid peptide release and/or its synthesis
JP2003513958A (ja) * 1999-11-09 2003-04-15 イーライ・リリー・アンド・カンパニー β−アミロイドペプチド放出および／またはその合成を阻害するために有用なβ−アミノ酸化合物
UA74849C2 (en) * 2000-11-17 2006-02-15 Lilly Co Eli Lactam
CA2425558C (en) * 2000-11-17 2012-01-03 Eli Lilly And Company Lactam compound
UA77165C2 (en) * 2000-11-17 2006-11-15 Lilly Co Eli (n)-((s)-2-hydroxy-3-methyl-butyryl)-1-(l-alaninyl)-(s)-1-amino-3-methyl-4,5,6,7-tetrahydro-2h-3-benzazepin-2-one dihydrate, processes for manufacturing and pharmaceutical composition

Also Published As

Publication number Publication date
EP1341531A2 (en) 2003-09-10
ES2278804T3 (es) 2007-08-16
DE60126132D1 (de) 2007-03-08
CA2427227C (en) 2010-08-17
AR035927A1 (es) 2004-07-28
HRP20030383B1 (hr) 2007-12-31
AU2002243192B2 (en) 2006-07-20
DE60126132T2 (de) 2007-10-18
EP1341531B1 (en) 2007-01-17
HK1059731A1 (en) 2004-07-16
PL362688A1 (en) 2004-11-02
MXPA03004292A (es) 2004-02-12
WO2002047671A3 (en) 2003-03-06
HU228117B1 (en) 2012-11-28
IL155960A0 (en) 2003-12-23
HRP20030383A2 (en) 2005-10-31
TWI305204B (en) 2009-01-11
KR100819679B1 (ko) 2008-04-04
HUP0301842A2 (hu) 2003-09-29
DZ3453A1 (fr) 2002-06-20
BR0115427A (pt) 2003-10-07
NO20032236L (no) 2003-07-10
EA200300580A1 (ru) 2003-10-30
NO20032236D0 (no) 2003-05-16
ZA200303789B (en) 2004-08-16
CN1486184A (zh) 2004-03-31
CA2427227A1 (en) 2002-06-20
SI1341531T1 (sl) 2007-06-30
SK288065B6 (sk) 2013-04-03
PE20020802A1 (es) 2002-09-10
EA005954B1 (ru) 2005-08-25
IL155960A (en) 2009-06-15
KR20030051846A (ko) 2003-06-25
UA74849C2 (en) 2006-02-15
SK5592003A3 (en) 2003-12-02
AU4319202A (en) 2002-06-24
CY1106366T1 (el) 2011-10-12
MY134559A (en) 2007-12-31
JP4116437B2 (ja) 2008-07-09
JP2004517090A (ja) 2004-06-10
US20050261495A1 (en) 2005-11-24
PL212199B1 (pl) 2012-08-31
NZ525854A (en) 2004-06-25
WO2002047671A2 (en) 2002-06-20
CZ20031351A3 (cs) 2003-11-12
NO324324B1 (no) 2007-09-24
DK1341531T3 (da) 2007-05-14
HUP0301842A3 (en) 2010-03-29
PT1341531E (pt) 2007-04-30

Similar Documents

Publication Publication Date Title
ECSP034600A (es) Compuestos de lactama
HN1999000154A (es) 1,2,3,4 tetrahidroquinolinas 2 sustituidas 4 - carboxiamino sustituidas.
NO20053246D0 (no) Kondensert 1,3-dihydroimidazol-ringforbindelse.
DE60135387D1 (de) 7,9 substituierte tetracyclinverbindungen
MY126559A (en) Fungicidal 2-methoxybenzophenones
BR0216099B1 (pt) "conjunto de desgaste".
DE50202328D1 (de) Amidofunktionelle aminopolydiorganosiloxane
DE60225341D1 (de) Neue 1,2,4-triazolverbindung
ES2172864T3 (es) 2-metoxibenzofenonas fungicidas.
CY1106682T1 (el) Ενωση λακταμης
ATE403429T1 (de) Spiropyrazol-verbindungen
MXPA04003886A (es) Tiofen- y tiazolsulfonamidas como agentes antineoplasticos.
PT1389213E (pt) Formulacoes de 3,7-diazabiciclo 3,3,1¿ como compostos antiarritmicos
AR028248A1 (es) Nuevos compuestos 2,3,4,5-tetrahidro-1h-(1,4) diazepino (1,7-a) indol
SV2003000981A (es) Fenil-heterociclil-eteres ref. pcs10973
TR199901017A2 (xx) B�cek ilac� terkibi.
EA200100854A1 (ru) Кальций-литические соединения
GB9918429D0 (en) Organic compounds
MXPA03009315A (es) 1.3-dionas carbociclicas tiazolil-substituidas como agentes pesticidas.
BR0205298B1 (pt) máquina de semeadura.
DE60213084D1 (de) 3,7-DIAZABICYCLOc3.3.1Ü-FORMULIERUNGEN ALS ANTIARRHYTHMIKA
ITTO20020747A1 (it) Composizione.
DK1497256T3 (da) Substituerede 1,5-diaminopentan-3-ol-forbindelser
ITTO20020745A1 (it) Composizione.
IT1303333B1 (it) Sottopiede per calzature.